Biopharma Data Management Strategies to Effectively Use AI Tools

10:45am - 11:15 am
Convergence and Critical Mass: The Fusion Moment for Biopharma and Data
The AbbVie Research Convergence Hub data sharing program between organizations was launched to correlate all R&D pipeline data, discovery data, RWD, and clinical patient data in a knowledge graph form that takes out the chemical compounds and then make it available to all (pharma, startups, universities). The goal is to create an open data science share that will ultimately help patients.

Harry Glorikian, General Partner, New Ventures Fund & Author: MoneyBall Medicine interviews:
Brian S. Martin, Head of AI R&D Information Research, Research Fellow, Abbvie

----

11:15am - 11:50am
Data Curation and Privacy

Belen Fraile, MD, MSC, VP & Head, US Oncology Strategic Data & Digital, Novartis Oncology
Anna Langhorne, PhD, Esq, Global Privacy Counsel, Regeneron Pharmaceuticals

----

11:50 - 12:15
Using AI to Generate Patient Data: How Digital Twins are Shaping Clinical Trials
Digital twins are AI-generated placebo patient data perfectly matched to actual trial patients. With a universal goal of being able to run better and faster clinical trials, this session will use an Alzheimer’s use case to demonstrate how digital twins can ultimately result in increased confidence in trial results.

Charles Fisher, PhD, Founder & CEO, Unlearn.AI

----

12:15 - 1:15
Drug Development using RWE, Integrated Research Platforms and Advanced Analyitcs/AI
An interactive discussion examining the opportunities created when AI tools/technologies and digital platforms are used to evaluate global data in real time:

• Revisiting the old science of the 'parallel line'
• Getting to what a drug works on, who it works on and the level of disease it works
on using advanced analytics to evaluate the diversity of patients of whole population
• Applying AI in regulatory oversight: How regulatory centaurs present a real opportunity for faster and more accurate drug reviews

Thomas Bock, MD, MBA, Founder & Past CEO, HeritX, Inc., Chair, Healthcare Advisory Board, Columbia Business School; Former SVP, Global Head of Medical Affairs, Alexion; Co-Founder, The APANDEMIC Initiative
Ülo Palm, MD, PhD, Chief Medical Officer and co-founder, Ordaos Bio; Co-Founder The APANDEMIC Initiative
Peter Pitts, Former Associate Commissioner FDA, Visiting Professor, Université Paris Descartes Medical School, Chair of Innovation Management & Healthcare Performance